Free Trial

60 Degrees Pharmaceuticals (SXTP) Competitors

60 Degrees Pharmaceuticals logo
$1.47 +0.02 (+1.38%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$1.47 0.00 (-0.27%)
As of 10/24/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SXTP vs. PMN, THAR, SNYR, AYTU, RLYB, IBIO, PRPH, ALLR, CASI, and TRAW

Should you be buying 60 Degrees Pharmaceuticals stock or one of its competitors? The main competitors of 60 Degrees Pharmaceuticals include Promis Neurosciences (PMN), Tharimmune (THAR), Synergy CHC (SNYR), Aytu BioPharma (AYTU), Rallybio (RLYB), iBio (IBIO), ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), CASI Pharmaceuticals (CASI), and Traws Pharma (TRAW). These companies are all part of the "pharmaceutical products" industry.

60 Degrees Pharmaceuticals vs. Its Competitors

Promis Neurosciences (NASDAQ:PMN) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Promis Neurosciences has higher earnings, but lower revenue than 60 Degrees Pharmaceuticals. Promis Neurosciences is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Promis NeurosciencesN/AN/A$2.78M-$0.21-2.05
60 Degrees Pharmaceuticals$300K20.09-$7.95M-$50.41-0.03

Promis Neurosciences presently has a consensus price target of $4.33, indicating a potential upside of 904.25%. 60 Degrees Pharmaceuticals has a consensus price target of $3.00, indicating a potential upside of 104.08%. Given Promis Neurosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Promis Neurosciences is more favorable than 60 Degrees Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Promis Neurosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
60 Degrees Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Promis Neurosciences has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -976.86%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Promis Neurosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Promis NeurosciencesN/A -266.69% -131.59%
60 Degrees Pharmaceuticals -976.86%N/A -133.88%

Promis Neurosciences has a beta of -0.17, indicating that its share price is 117% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.79, indicating that its share price is 179% more volatile than the S&P 500.

50.1% of Promis Neurosciences shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 3.8% of Promis Neurosciences shares are held by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 3 mentions for 60 Degrees Pharmaceuticals and 2 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.95 beat 60 Degrees Pharmaceuticals' score of 0.63 indicating that Promis Neurosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Promis Neurosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
60 Degrees Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Promis Neurosciences beats 60 Degrees Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get 60 Degrees Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SXTP vs. The Competition

Metric60 Degrees PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.03M$2.63B$6.22B$10.81B
Dividend YieldN/A57.77%5.72%4.81%
P/E Ratio-0.0327.9431.5030.91
Price / Sales20.09786.96594.92133.93
Price / CashN/A168.8137.2561.86
Price / Book-0.235.6512.056.61
Net Income-$7.95M$33.06M$3.34B$277.10M
7 Day Performance-1.34%3.16%1.93%2.57%
1 Month Performance5.76%8.14%7.77%3.79%
1 Year Performance-63.79%-2.49%56.40%33.01%

60 Degrees Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SXTP
60 Degrees Pharmaceuticals
1.9507 of 5 stars
$1.47
+1.4%
$3.00
+104.1%
-65.7%$6.03M$300K-0.033News Coverage
Analyst Forecast
Gap Up
PMN
Promis Neurosciences
3.6596 of 5 stars
$0.44
-2.1%
$4.33
+884.2%
-54.8%$24.21MN/A-2.105Analyst Forecast
Short Interest ↓
THAR
Tharimmune
1.9438 of 5 stars
$2.99
-5.4%
$17.00
+468.6%
+54.5%$24.04MN/A-0.492Analyst Forecast
Gap Up
SNYR
Synergy CHC
4.2647 of 5 stars
$2.53
flat
$10.00
+295.3%
-72.7%$23.84M$34.83M6.6640News Coverage
Analyst Downgrade
Short Interest ↓
AYTU
Aytu BioPharma
3.5554 of 5 stars
$2.36
-0.8%
$9.17
+288.4%
+5.6%$23.59M$66.38M-0.84160
RLYB
Rallybio
3.2812 of 5 stars
$0.56
+1.5%
$5.00
+792.9%
-38.6%$23.06M$640K-0.6040Analyst Forecast
Gap Up
IBIO
iBio
2.892 of 5 stars
$1.11
+24.3%
$4.00
+260.4%
-56.6%$22.48M$400K-0.64100News Coverage
Analyst Forecast
High Trading Volume
PRPH
ProPhase Labs
0.4953 of 5 stars
$0.51
-3.4%
N/A-83.3%$21.98M$6.77M-0.41130News Coverage
Analyst Forecast
Gap Up
ALLR
Allarity Therapeutics
2.7054 of 5 stars
$1.48
-2.0%
$9.25
+525.0%
-4.8%$21.93MN/A0.0010News Coverage
Analyst Forecast
CASI
CASI Pharmaceuticals
3.9683 of 5 stars
$1.71
-3.9%
$4.00
+133.9%
-72.1%$21.89M$28.54M-0.59180News Coverage
TRAW
Traws Pharma
0.9075 of 5 stars
$2.98
-2.9%
N/A-46.4%$21.88M$230K0.0317Positive News

Related Companies and Tools


This page (NASDAQ:SXTP) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners